HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

在一组健康的绝经后妇女中， 身体脂肪量独立地从下（gynoid）到上（android） 分布和从低（瘦）到高（肥胖）脂肪百分比，我们有 发现随着年龄的增长，身体脂肪百分比有增加的趋势， 年龄和体重指数之间没有显著关系。 数据还表明，双能X线吸收测定法可估计 身体组成与通过水密度测定法获得的结果相当。 那里 与腰臀比呈独立负相关（P<0.03）， 不符合体重指数年龄，12小时脉冲GH水平和GHRH- 刺激GH峰。 这些发现表明， 绝经后女性生长激素分泌与男性化体质的关系 口服 雌激素治疗，产生了增加自发GH水平的趋势， 这仅对峰下面积有意义。 透皮 雌激素有降低GH平均峰值幅度的趋势， 平均GH。 口服，但不透皮，雌激素显着减少 基础和刺激IGF-I，而经皮雌激素有更大的 降低IGF结合蛋白-3的作用。 在 另一项正在进行的研究，年龄65-75岁的健康女性接受恒定的 联合口服雌激素与和不与每日低剂量的小剂量炔雌醇 乳房触痛是迄今为止报告的唯一不良反应。 四 接受雌激素-孕激素联合治疗的妇女发生阴道出血 在研究的前三个月内，需要增加 次给药结束

In a group of healthy postmenopausal women whose body fat distribution and body fat mass independently range from lower (gynoid) to upper (android) distribution and from lower (lean) to higher (obese) percent fat we have found a trend to greater percent body fat with increasing age despite the absence of a significant relationship between age and body mass index. Data also suggest that dual energy x-ray absorptiometry yields estimates of body composition comparable to those obtained by hydrodensitometry. There were independent inverse correlations of waist to hip ratio (p<0.03), but not of age of body mass index, with 12 hour pulsatile GH levels and GHRH- stimulated GH peaks. These findings suggest an age-independent decrease in GH secretion attributable to android habitus in postmenopausal women. Oral estrogen treatment, produced a trend to increased spontaneous GH levels, which was significant only for the area under the peaks. Transdermal estrogens tended to decrease mean GH peak amplitude, and to increase 12 h mean GH. Oral, but not transdermal, estrogens significantly decreased basal and stimulated IGF-I, while transdermal estrogens had a greater effect on reducing IGF Binding Protein-3 than did oral estrogens. In another ongoing study of healthy women age 65-75 y treated with constant combined oral estrogen with and without low dose daily progestin, minor breast tenderness has been the only adverse effect reported to date. Four women receiving estrogen-progestin co-therapy experienced vaginal bleeding within the first three months of study requiring an increase in progestin dose.